Proposed Intended-Use Amendments Invite Questions About FDA's Off-Label Intentions
This article was originally published in The Gray Sheet
Executive Summary
The agency issued a proposed rule addressing tobacco regulation last month that also includes amendments regarding "intended uses" of devices and drugs. It could offer an opportunity for companies to get more clarity from FDA on off-label promotion issues. But one attorney says it's frustrating that FDA neglected to incorporate any recent feedback from the courts that its enforcement of off-label marketing runs afoul of the First Amendment.
You may also be interested in...
Experts Debate Prospects Of Third-Party Agency To Oversee Off-Label Communications
The Duke-Margolis Center has released a list of policy changes that experts argue could improve how off-label communication is disseminated. Among the proposals is a third-party organization to vet off-label communication and a tiered labeling system.
In Case You Missed It: Top 10 "Gray Sheet" Stories In October
Our most popular stories last month focused on how device firms respond to FDA inspection reports; guidelines from the agency on how to handle manufacturing site changes; product labeling matters; and off-label marketing rules, among other topics.
Device Firms Should Not Ignore Pharma Off-Label Suits, Experts Say
While recent case law that appears to give industry more leverage in off-label communications involves drugs, the precedent should apply equally to devices, attorneys say. Nonetheless, companies should be cautious about moving full-steam ahead with off-label promotions